Overactivation of the alternative complement pathway contributes to IgA nephropathy and glomerular inflammation. In the 9-month interim analysis of this phase 3 trial, iptacopan, a complement factor B ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results